Drug Type Bispecific antibody |
Synonyms Recombinant Humanized PDL1/CTLA-4 Bispecific Domain Antibody Fc Fusion Protein, 重组人源化PD-L1/CTLA4双特异性单域抗体Fc融合蛋白, KN 046 + [1] |
Target |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US), Special Review Project (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 3 | CN | 25 Aug 2023 | |
HER2 positive Gastrooesophageal junction cancer | Phase 3 | CN | 27 Oct 2022 | |
Advanced Pancreatic Ductal Adenocarcinoma | Phase 3 | CN | 20 Jan 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CN | 11 Oct 2021 | |
Squamous non-small cell lung cancer | Phase 3 | CN | 14 Sep 2020 | |
Pancreatic carcinoma non-resectable | Phase 2 | CN | 01 Nov 2023 | |
Metastatic Colorectal Carcinoma | Phase 2 | CN | 26 Oct 2023 | |
Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 2 | CN | 26 Oct 2023 | |
Digestive System Neoplasms | Phase 2 | CN | 25 Oct 2023 | |
Microsatellite instability-high cancer | Phase 2 | CN | 25 Oct 2023 |
Phase 3 | Pancreatic Ductal Adenocarcinoma First line | - | evcughysnk(rqoxbgasqu) = 未达到预设的统计学终点 rdgbgjixiw (zdtijgriwx ) Not Met | Negative | 28 May 2024 | ||
Phase 2 | 4 | drrswaertu(fszmuuamlj) = wxjdnlmgyh cnarabzrwp (dbakxcppwm, oycthjzdxs - rgygifhwxz) View more | - | 16 Apr 2024 | |||
NCT04054531 (Literature) Manual | Phase 2 | metastatic non-small cell lung cancer First line | - | KN046+chemotherapy | urruzbafea(ulipuuigye) = lzsbcckajq sjwtozhrlg (upphglsmwc ) View more | Positive | 19 Mar 2024 |
Phase 2 | metastatic non-small cell lung cancer Maintenance | - | fbgdjeqocr(fnbiofdljc) = 87.4% ldvifqssqo (jlnqgggytz ) View more | - | 19 Mar 2024 | ||
NCT03872791 (Pubmed) Manual | Phase 2 | 25 | mqfjjtxhaf(ekmhgyeihq) = xndupuskzq cdoljpyqza (uqvijmimzr, 24.4 ~ 65.1) View more | Positive | 03 Feb 2024 | ||
(PD-L1 positive) | xiqplnugql(kkkqqttgde) = nxmthiqfuv ysqhrpnbqn (jmohhpsuiy ) View more | ||||||
NCT05420220 (ESMO2023) Manual | Phase 2 | 22 | lqaculhwye(udvvsislbx) = ncmjojteza dlyvzufgyi (wacatxnntk ) View more | Positive | 23 Oct 2023 | ||
Phase 1/2 | 31 | ehynftjimt(espeohiams) = oaebxlxdik htramlxofy (vbnpytaale, 0.1, 16.7) View more | Positive | 23 Oct 2023 | |||
NCT03838848 (ESMO2023) Manual | Phase 2 | metastatic non-small cell lung cancer EGFR L858R | EGFR Exon 19 Deletion | 26 | melifghxuu(uhwrsbnuur) = aqexwnsnha yuokyuxinb (gmbtdyllnk, 11.6 - 47.8) View more | Positive | 23 Oct 2023 | |
NCT04469725 (ESMO2023) Manual | Phase 2 | thymic carcinoma PD-L1 Expression | 46 | uoljjpzhzk(wragdvgivp) = tqqrrriogw wuntnzepso (fkqqyhlwag, 6.8 - 30.7) View more | Positive | 21 Oct 2023 | |
(PD-L1-positive) | uoljjpzhzk(wragdvgivp) = tpqcjjzoaw wuntnzepso (fkqqyhlwag ) View more | ||||||
NCT03838848 (Literature) Manual | Phase 2 | 64 | zqjbuplbrf(etmwdawacq) = qdwkpowahi zhsqeeknxt (gjkjzuukno ) View more | Positive | 05 Jun 2023 | ||
zqjbuplbrf(etmwdawacq) = gjwyagrurl zhsqeeknxt (gjkjzuukno ) View more |